

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Sincere Pharmaceutical Group Limited

先聲藥業集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock code: 2096)

VOLUNTARY ANNOUNCEMENT

APPROVAL OF INVESTIGATIONAL NEW DRUG FOR SIM0501 (AN USP1 SMALL-MOLECULE INHIBITOR) ISSUED BY U.S. FOOD AND DRUG ADMINISTRATION

This announcement is made by Sincere Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform shareholders and potential investors of the Company about the latest business development of the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that, on December 2, 2023, Beijing Time, SIM0501, a small-molecule inhibitor of Ubiquitin Specific Peptidase 1 (“**USP1**”), which is an anti-tumor drug candidate independently developed by the Group, has obtained the approval of the Investigational New Drug (“**IND**”) application issued by the U.S. Food and Drug Administration (FDA). SIM0501 is intended to be investigated in the clinical trials for advanced solid tumors. In addition, the IND application of SIM0501 in China was accepted by the National Medical Products Administration (國家藥品監督管理局) of China on October 27, 2023.

ABOUT SIM0501

SIM0501 is an oral, non-covalent and highly selective inhibitor of USP1. USP1 is found to be overexpressed in various tumors and plays a key role in DNA damage response and repair. The inhibition of USP1 can promote apoptosis in tumors, especially in the tumors with homologous recombination deficiency (“**HRD**”). Following the success of PARP inhibitor (“**PARPi**”), the USP1 inhibitor is expected to provide innovative solutions for more patients with solid tumors in the field of “synthetic lethality”. In preclinical *in vitro* and *in vivo* pharmacology studies, SIM0501 has shown significant anti-proliferation activity against HRD tumors as a monotherapy or in combination with PARPi, which demonstrates high potential for clinical development.

ABOUT THE COMPANY

The Company is an innovation and R&D-driven pharmaceutical company and has established a “State Key Laboratory of Neurology and Oncology Drug Development”. The Company focuses on the therapeutic areas of oncology, nervous system, autoimmune and anti-infection, with forward-looking layout of disease areas that may have significant clinical needs in the future, aiming to achieve the mission of “providing today’s patients with medicines of the future”. Driven by its in-house R&D efforts and synergistic innovation, the Company has established strategic cooperation partnerships with many innovative companies and research institutes.

By order of the Board
Sincere Pharmaceutical Group Limited
Mr. Ren Jinsheng
Chairman and Chief Executive Officer

Hong Kong, December 4, 2023

As at the date of this announcement, the Board comprises Mr. REN Jinsheng as the Chairman and executive Director, Mr. TANG Renhong, Mr. WAN Yushan and Ms. WANG Xi as the executive Directors; Mr. SONG Ruilin, Mr. WANG Jianguo, Mr. WANG Xinhua and Mr. SUNG Ka Woon as the independent non-executive Directors.